CTA

Trucking Execs to Freeland: Enforce the Law Against Illegal Driver Inc

Retrieved on: 
Lundi, avril 8, 2024
Government, Letter, Growth, Federation, CTA

The carriers, who play pivotal roles on executive committees at the CTA and provincial association level, represent nearly 55,000 Canadian workers, nationwide.

Key Points: 
  • The carriers, who play pivotal roles on executive committees at the CTA and provincial association level, represent nearly 55,000 Canadian workers, nationwide.
  • This scheme gives rise to the largest underground economy of any federally regulated sector.
  • “We are not bluffing when we say that Driver Inc. has reached crisis level for our industry.
  • We conservatively estimate that over one-third of the trucking fleets in certain parts of the country employ the scheme – and that rate is growing rapidly,” the carriers wrote.

GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Lundi, avril 1, 2024
Research, Conference, Lupus, Inflammation, Patient, Food and Drug Administration, CTA, Doctor of Philosophy, SLE, Insurance, GRI, IPF, Fibrosis, Oxygen, Immune system, Injury, NKT, Food, Movement, Lupus nephritis, Autoimmune disease, Natural killer T cell, Medication, Pharmaceutical industry

LA JOLLA, CA, April 01, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today reported its financial results for the fiscal year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • IPF is a rare chronic progressive pulmonary disease with abnormal scarring of the lung blocking the movement of oxygen into the bloodstream.
  • GRI Bio’s lead program, GRI-0621, is a small molecule RAR-βɣ dual agonist that inhibits the activity of human iNKT cells.
  • Research and development expenses were $3.2 million and $0.2 million for the years ended December 31, 2023 and 2022, respectively.
  • General and administrative expenses were $8.2 million and $2.0 million for the years ended December 31, 2023 and 2022, respectively.

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Retrieved on: 
Mardi, mars 26, 2024
Piz, AATD, Mutation, Biotechnology, Patient, Lung, CTA, AAT, Life expectancy, Safety, Pharmacokinetics, Liver, Medication, Pharmaceutical industry

CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the clearance of its clinical trial authorisation (CTA) application by the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency for BEAM-302, an in vivo base editor, as a potential treatment for patients with alpha-1 antitrypsin deficiency (AATD).

Key Points: 
  • CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the clearance of its clinical trial authorisation (CTA) application by the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency for BEAM-302, an in vivo base editor, as a potential treatment for patients with alpha-1 antitrypsin deficiency (AATD).
  • “AATD is an inherited genetic condition that can cause serious lung and liver disease, which can lead to significant debility and reduced life expectancy for patients.
  • The study design includes a dose exploration portion followed by a dose expansion portion to identify the optimal dose to take forward in a pivotal study.
  • The company expects to initiate the Phase 1/2 trial of BEAM-302 in the UK in the first half of 2024.

Qnovia, Inc. Announces the Appointment of Four New Members to its Scientific Advisory Board

Retrieved on: 
Mardi, avril 9, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Tobacco, Clinical Trials, Retail, Disease, Cardiovascular Research, Society, IND, Psychology, Therapy, Senior counsel, Population health, School, Dean (education), Partnership, Nicotine, Policy, Smoker, Behavior, NIH, Brown University, Trial of the century, University, SAB, Pharmacology, Homelessness, San Francisco General Hospital, UCSF, Public, Cancer, MD, Publication, Heated tobacco product, Hospital, Juul, FDA, Alpert Medical School, Pregnancy, Chair, Public health, University of Kansas, Cardiology, CTA, Mortality, Louisiana State University, Doctor of Philosophy, MHRA, Smoking, Toxicology, Division, Brown, Social science, Pharmaceutical industry

“We believe our proprietary drug-device combination platform has the potential to be a first-in-class and best-in-class treatment for smoking cessation.

Key Points: 
  • “We believe our proprietary drug-device combination platform has the potential to be a first-in-class and best-in-class treatment for smoking cessation.
  • Last fall, QN-01 demonstrated a superior pharmacokinetic profile compared to existing nicotine replacement therapies in our first-in-human Phase 1 clinical trial.
  • We plan to submit our IND and CTA to the regulatory bodies and look forward to commencing our Phase 1/2 clinical study this year.
  • He also served a three-year term on the Board of the Society for Research on Nicotine and Tobacco.

Wolters Kluwer Experts to Provide Insights on U.S. Corporate Transparency Act Compliance

Retrieved on: 
Lundi, avril 8, 2024
Professional Services, Business, Other Professional Services, Legal, Consulting, Accounting, Beneficial ownership, Environment, Associate, Wolters Kluwer, Risk, CTA, CT Corporation, EDT, Disclosure, Product management, Corporate transparency, Property management

Experts from Wolters Kluwer CT Corporation are set to offer insights on how new beneficial ownership reporting requirements under the U.S. Corporate Transparency Act (CTA) are impacting U.S. trusts, nonprofits, startups and subsidiaries in a webinar Thursday, May 2, 1-2 pm EDT.

Key Points: 
  • Experts from Wolters Kluwer CT Corporation are set to offer insights on how new beneficial ownership reporting requirements under the U.S. Corporate Transparency Act (CTA) are impacting U.S. trusts, nonprofits, startups and subsidiaries in a webinar Thursday, May 2, 1-2 pm EDT.
  • Our presenters will discuss these issues in detail to help impacted businesses comply with the new reporting requirements,” said Rupak Venugopal , Vice President, Beneficial Ownership, Wolters Kluwer Financial & Corporate Compliance.
  • Presenters include two experts from Wolters Kluwer CT Corporation - Sandra Feldman , Publications Attorney, and Anirudh Koshi John , Associate Director of Product Management.
  • More information is available on the dedicated Wolters Kluwer resource page, “ Beneficial Ownership Information Compliance from CT Corporation .”
    For more information about Wolters Kluwer, please visit: www.wolterskluwer.com .

Urgent Action Needed for Commercial Truck Driver Training

Retrieved on: 
Mardi, avril 9, 2024
MNP, Risk management, Insurance, CTA, Research, Food, Truck, Senior, Accident, Insurance Bureau of Canada, Safety, IBC, Map

Insurance Bureau of Canada (IBC) commissioned MNP, one of Canada's leading professional services firms, to identify the key factors impacting the cost of insurance for commercial truck operators.

Key Points: 
  • Insurance Bureau of Canada (IBC) commissioned MNP, one of Canada's leading professional services firms, to identify the key factors impacting the cost of insurance for commercial truck operators.
  • MNP found drivers with less training and experience are more likely to be involved in collisions and make costly claims than drivers with more training and experience.
  • To identify best practices in truck driver training, MNP conducted a review of driver training programs in various Canadian and international jurisdictions.
  • Other recommendations in the report include piloting the use of telematics to provide feedback to commercial truck drivers, and adopting a graduated or progressive licensing system.

Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates

Retrieved on: 
Mardi, mars 19, 2024
Diary, Patient, IND, Adolescence, Pediatrics, Therapy, FAAP, Rett syndrome, Research, Central nervous system, Risk, Webcast, CNS, Ageing, CHU, Safety, AAV, Mutation, Development, MECP2, Disease, Associate, Sleep, Șaeș, Dysrhythmia, FRCP, MTD, Movement, IDMC, VG, Hyperventilation, Principal, Administration, Index, Seizure, CTA, Female, MHRA, Phenotype, ID, Frasier, Pharmaceutical industry

Notably, she has vastly increased interest in social communication and activities at week 35 compared to earlier post-treatment assessments.

Key Points: 
  • Notably, she has vastly increased interest in social communication and activities at week 35 compared to earlier post-treatment assessments.
  • Dr. Schultz is a board-certified, licensed pediatric neurologist experienced in treating patients with Rett syndrome and leading gene therapy clinical trials.
  • She brings more than 17 years of clinical experience and will lead the Company’s clinical development, clinical operations, medical affairs and safety activities.
  • ET to review its financial and operating results and to provide corporate and clinical updates.

Landmarks Illinois grants awarded to South Side preservation projects in Bronzeville, Englewood and Jackson Park

Retrieved on: 
Jeudi, mars 14, 2024
Jogging, Culture, Organization, Walking, CTA, History, Clarence Darrow, House, Architecture

CHICAGO, March 14, 2024 (GLOBE NEWSWIRE) -- Landmarks Illinois has awarded three grants through the Timuel D. Black, Jr. Grant Fund for Chicago’s South Side to projects aimed at preserving historic sites in Bronzeville, Englewood and Jackson Park.

Key Points: 
  • CHICAGO, March 14, 2024 (GLOBE NEWSWIRE) -- Landmarks Illinois has awarded three grants through the Timuel D. Black, Jr. Grant Fund for Chicago’s South Side to projects aimed at preserving historic sites in Bronzeville, Englewood and Jackson Park.
  • Englewood Real Estate Development Corp., Englewood: $2,500 matching grant for temporary roof repairs to the Englewood Schlitz Tied House — one of the last remaining pre-prohibition Schlitz Brewing taverns that remain in the city, which is being restored to serve as a community gathering space.
  • Jackson Park Watch, Jackson Park: $2,000 matching grant to conduct a structural assessment of the Clarence Darrow Bridge to help determine a preservation plan for the bridge, parts of which predate the World Columbian Exposition of 1893.
  • Grants through the Landmarks Illinois Timuel D. Black, Jr. Grant Fund for Chicago’s South Side range from $500 - $2,500 each, depending on need, and require a one-to-one match.

HeartFlow Announces Publication of 10-year Follow-Up Data from the DISCOVER-FLOW Study in the Journal of Cardiovascular Computed Tomography

Retrieved on: 
Mardi, mars 12, 2024
Diagnosis, FACC, Coronary artery disease, Risk, Patient, Atherosclerosis, CTA, Journal, Artificial intelligence, FFR, AI, Fierce, Safety, Trailblazer, CAD, Medical device

MOUNTAIN VIEW, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced that 10-year follow-up data from its DISCOVER-FLOW study were published in the Journal of Cardiovascular Computed Tomography.

Key Points: 
  • MOUNTAIN VIEW, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced that 10-year follow-up data from its DISCOVER-FLOW study were published in the Journal of Cardiovascular Computed Tomography .
  • The company has spent the last decade working with clinicians to improve CAD diagnosis, making significant progress validated by high quality clinical evidence.
  • HeartFlow’s approach is centered around scientific rigor with peer-reviewed publications to provide confidence and certainty to clinicians and the patients they serve.
  • Together, this comprehensive solution offers valuable data not currently available with other non-invasive diagnostic tools or CTA-based AI analyses.

Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

Retrieved on: 
Mardi, mars 12, 2024
Human, Obesity, Disease, Diabetes, Weight loss, CTA, Mouse, T2D, Therapy, DSM-IV codes, Pharmaceutical industry

BURLINGTON, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced promising new preclinical findings for the first clinical candidate in its Rejuva® pancreatic gene therapy platform. RJVA-001 is the Company’s first GLP-1 gene therapy candidate to emerge from the platform, setting the stage for a potentially transformative approach to treating metabolic diseases, including obesity and T2D.

Key Points: 
  • Data provides first demonstration of glucose lowering and weight loss potency from pancreas-produced native human GLP-1, highlighting the capacity of pancreatic GLP-1 to provide metabolic control.
  • These results with a native, short half-life human GLP-1 sequence to be used in RJVA-001 build upon earlier results with a prototype transgene GLP-1 analogue.
  • RJVA-001 is the Company’s first GLP-1 gene therapy candidate to emerge from the platform, setting the stage for a potentially transformative approach to treating metabolic diseases, including obesity and T2D.
  • The Company has reached alignment with European regulators on the use of this efficacy model to support the submission of a Clinical Trial Application (CTA) in Europe.